Combination of kinase inhibitors and uses thereof
The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.
1. A method for treating breast cancer in a subject in need thereof comprising administering orally to the subject a therapeutically effective amount of lapatinib and a therapeutically effective amount of a PI3-kinase α inhibitor having the following structure:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein lapatinib and PI3-kinase α inhibitor are administered simultaneously or sequentially.
3. The method of claim 2 , wherein the method is administered daily.
4. The method of claim 3 , wherein the method is administered for 21 days.